J. David Boyle II is an experienced leader in the finance sector, particularly in biopharmaceuticals. He earned a Bachelor of Arts from Catholic University and has held prominent roles at major companies, including XOMA Ltd. and Polycom, Inc. His tenure...

J. David Boyle II is an experienced leader in the finance sector, particularly in biopharmaceuticals. He earned a Bachelor of Arts from Catholic University and has held prominent roles at major companies, including XOMA Ltd. and Polycom, Inc. His tenure as the Chief Financial Officer at Sarepta Therapeutics, Inc. coincided with a significant period of growth. In 2010, he briefly stepped in as the Interim CEO, guiding the company through management transitions. Notably, under his guidance, Sarepta worked on groundbreaking projects related to RNA therapeutics, including clinical trials for genetic diseases like Duchenne Muscular Dystrophy. His practical experience in handling corporate finances and operations has been crucial for the company, especially around times of strategic change. His compensation package reflects a balance of fixed salary and performance incentives, ensuring that his interests align with the company’s success. Overall, Boyle’s background positions him as a knowledgeable asset in the biotech world, especially for investors keen on innovative health solutions.